247 related articles for article (PubMed ID: 31498178)
1. Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the Breast.
Harrison BT; Fowler E; Krings G; Chen YY; Bean GR; Vincent-Salomon A; Fuhrmann L; Barnick SE; Chen B; Hosfield EM; Hornick JL; Schnitt SJ
Am J Surg Pathol; 2019 Dec; 43(12):1693-1700. PubMed ID: 31498178
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.
Hung YP; Jo VY; Hornick JL
Histopathology; 2019 Jul; 75(1):54-62. PubMed ID: 30801752
[TBL] [Abstract][Full Text] [Related]
3. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland.
Bell D; Ferrarotto R; Liang L; Goepfert RP; Li J; Ning J; Broaddus R; Weber RS; El-Naggar AK
Virchows Arch; 2020 Feb; 476(2):295-305. PubMed ID: 31423558
[TBL] [Abstract][Full Text] [Related]
4. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors.
Csanyi-Bastien M; Lanic MD; Beaussire L; Ferric S; François A; Meseure D; Jardin F; Wassef M; Ruminy P; Laé M
Am J Surg Pathol; 2021 Nov; 45(11):1487-1498. PubMed ID: 33899788
[TBL] [Abstract][Full Text] [Related]
5. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
[TBL] [Abstract][Full Text] [Related]
6. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
[TBL] [Abstract][Full Text] [Related]
7. Using pan-TRK and RET Immunohistochemistry for the Detection of Fusion Types of Salivary Gland Secretory Carcinoma.
Su YJ; Lee YH; Jin YT; Hsieh MS
Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):264-272. PubMed ID: 35384876
[TBL] [Abstract][Full Text] [Related]
8. Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion.
Xu B; Haroon Al Rasheed MR; Antonescu CR; Alex D; Frosina D; Ghossein R; Jungbluth AA; Katabi N
Histopathology; 2020 Feb; 76(3):375-382. PubMed ID: 31448442
[TBL] [Abstract][Full Text] [Related]
9. Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma.
Ye Q; Chen H; Han C; Peng Y; Huang X; Sun H; Wu Y; Albarracin CT; Middleton LP; Sahin AA; Huo L; Ding Q
J Clin Pathol; 2023 Aug; ():. PubMed ID: 37586834
[TBL] [Abstract][Full Text] [Related]
10. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
Rudzinski ER; Lockwood CM; Stohr BA; Vargas SO; Sheridan R; Black JO; Rajaram V; Laetsch TW; Davis JL
Am J Surg Pathol; 2018 Jul; 42(7):927-935. PubMed ID: 29683818
[TBL] [Abstract][Full Text] [Related]
11. Secretory Breast Carcinoma: A Histopathologic and Genomic Spectrum Characterized by a Joint Specific ETV6-NTRK3 Gene Fusion.
Del Castillo M; Chibon F; Arnould L; Croce S; Ribeiro A; Perot G; Hostein I; Geha S; Bozon C; Garnier A; Lae M; Vincent-Salomon A; MacGrogan G
Am J Surg Pathol; 2015 Nov; 39(11):1458-67. PubMed ID: 26291510
[TBL] [Abstract][Full Text] [Related]
12. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.
Lee YC; Chen JY; Huang CJ; Chen HS; Yang AH; Hang JF
Endocr Pathol; 2020 Dec; 31(4):348-358. PubMed ID: 32880785
[TBL] [Abstract][Full Text] [Related]
13. Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion.
Skálová A; Vanecek T; Simpson RH; Laco J; Majewska H; Baneckova M; Steiner P; Michal M
Am J Surg Pathol; 2016 Jan; 40(1):3-13. PubMed ID: 26492182
[TBL] [Abstract][Full Text] [Related]
14. Secretory breast carcinoma in a female adult with liver metastsis: a case report and literature review.
Lian J; Wang LX; Guo JH; Bu P; Xi YF; Yun KM
Diagn Pathol; 2021 Oct; 16(1):89. PubMed ID: 34629079
[TBL] [Abstract][Full Text] [Related]
15. Non-secretory breast carcinomas lack NTRK rearrangements and TRK protein expression.
Remoué A; Conan-Charlet V; Bourhis A; Flahec GL; Lambros L; Marcorelles P; Uguen A
Pathol Int; 2019 Feb; 69(2):94-96. PubMed ID: 30707464
[TBL] [Abstract][Full Text] [Related]
16. Salivary Secretory Carcinoma Harboring a Novel ALK Fusion: Expanding the Molecular Characterization of Carcinomas Beyond the ETV6 Gene.
Sasaki E; Masago K; Fujita S; Suzuki H; Hanai N; Hosoda W
Am J Surg Pathol; 2020 Jul; 44(7):962-969. PubMed ID: 32205481
[TBL] [Abstract][Full Text] [Related]
17. Pan-TRK immunohistochemistry in gynaecological mesenchymal tumours: diagnostic implications and pitfalls.
Moura MS; Costa J; Velasco V; Kommoss F; Oliva E; Le Loarer F; McCluggage WG; Razack R; Treilleux I; Mills A; Longacre T; Devouassoux-Shisheboran M; Hostein I; Azmani R; Blanchard L; Hartog C; Soubeyran I; Khalifa E; Croce S
Histopathology; 2024 Feb; 84(3):451-462. PubMed ID: 37988282
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of pan-Trk immunohistochemistry for inflammatory myofibroblastic tumours.
Yamamoto H; Nozaki Y; Kohashi K; Kinoshita I; Oda Y
Histopathology; 2020 Apr; 76(5):774-778. PubMed ID: 31578734
[TBL] [Abstract][Full Text] [Related]
19. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
[TBL] [Abstract][Full Text] [Related]
20. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions.
Brčić I; Godschachner TM; Bergovec M; Igrec J; Till H; Lackner H; Scheipl S; Kashofer K; Brodowicz T; Leithner A; Szkandera J; Liegl-Atzwanger B
Mod Pathol; 2021 Feb; 34(2):396-407. PubMed ID: 32860002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]